ExodusPoint Capital Management LP lessened its stake in shares of CareDx, Inc (NASDAQ:CDNA – Free Report) by 17.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,466 shares of the company’s stock after selling 12,428 shares during the quarter. ExodusPoint Capital Management LP owned about 0.11% of CareDx worth $544,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in CareDx by 27.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,540 shares of the company’s stock valued at $109,000 after purchasing an additional 2,029 shares in the last quarter. American Century Companies Inc. purchased a new stake in CareDx in the 1st quarter valued at about $109,000. Lazard Asset Management LLC grew its holdings in CareDx by 32.0% in the 1st quarter. Lazard Asset Management LLC now owns 3,225 shares of the company’s stock valued at $119,000 after buying an additional 782 shares during the period. Alpine Global Management LLC acquired a new stake in shares of CareDx during the 4th quarter worth $121,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of CareDx in the 1st quarter worth $131,000.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. StockNews.com began coverage on CareDx in a report on Thursday, August 17th. They issued a “hold” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research report on Wednesday, August 9th. BTIG Research downgraded shares of CareDx from a “buy” rating to a “neutral” rating in a research report on Thursday, May 11th. Finally, Raymond James raised shares of CareDx from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Tuesday, August 15th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.60.
Insiders Place Their Bets
In other CareDx news, insider Reginald Seeto sold 14,268 shares of the firm’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $8.76, for a total transaction of $124,987.68. Following the completion of the transaction, the insider now directly owns 500,873 shares of the company’s stock, valued at approximately $4,387,647.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Peter Maag sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $10.34, for a total transaction of $51,700.00. Following the completion of the transaction, the director now directly owns 309,657 shares of the company’s stock, valued at $3,201,853.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Reginald Seeto sold 14,268 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $8.76, for a total value of $124,987.68. Following the transaction, the insider now directly owns 500,873 shares of the company’s stock, valued at $4,387,647.48. The disclosure for this sale can be found here. Insiders have sold 35,992 shares of company stock worth $339,996 in the last three months. 4.20% of the stock is owned by insiders.
CareDx Price Performance
Shares of CDNA stock opened at $8.81 on Thursday. CareDx, Inc has a 12 month low of $6.22 and a 12 month high of $20.71. The firm has a market capitalization of $477.24 million, a P/E ratio of -5.65 and a beta of 0.95. The company’s fifty day moving average price is $9.68 and its two-hundred day moving average price is $9.36.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.10. CareDx had a negative net margin of 27.15% and a negative return on equity of 19.84%. The firm had revenue of $70.30 million for the quarter, compared to analyst estimates of $56.40 million. On average, sell-side analysts anticipate that CareDx, Inc will post -2.25 EPS for the current year.
About CareDx
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Recommended Stories
- Five stocks we like better than CareDx
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- These Quality Dividend Kings Grow their Dividends the Fastest
- Retail Stocks Investing, Explained
- 3 Growth Stocks to Buy in September
- Best Restaurant Stocks to Invest in Now
- 3 Underappreciated Stocks with Nowhere to Go But Up
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNA – Free Report).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
